Trade CLYM stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Climb Bio, Inc. (CLYM) is trading at US$15.90, up 2.45% today as of Sep 8, 16:00 EDT. The company has a market capitalisation of US$992.5M. Over the past 52 weeks, CLYM has traded between US$1.54 and US$18.33. On Syfe you can trade CLYM with $0 commission and add it to your watchlist.
| Previous close | US$15.52 |
|---|---|
| Market cap | US$992.5M |
| 52-week range | US$1.54 – US$18.33 |
| Volume | 894.17K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Climb Bio, Inc.
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The firm develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
Year: 2021
Climb Bio, Inc. (CLYM) stock is trading at US$15.90, +2.45% from the previous close of US$15.52.
The market cap for Climb Bio, Inc. (CLYM) stock is approximately US$992.5M.
The 52-week high for Climb Bio, Inc. (CLYM) stock is US$18.33.
The 52-week low for Climb Bio, Inc. (CLYM) stock is US$1.54.
Climb Bio, Inc. (CLYM) does not currently pay a dividend.
Stay on top of CLYM
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
